Rasopatiler: Nöro-Kardiyo-Fasiyo-Kütanöz Sendromlar
Özet
Rasopatiler, hücre sinyal yolağı olan RAS/MAPK sistemindeki genetik mutasyonlardan kaynaklanan, benzer klinik özelliklere sahip bir hastalık grubudur. Noonan, Costello, Kardiyofasiyokutanöz sendrom ve Nörofibromatozis tip 1 gibi hastalıkları kapsayan bu sendromlar, genellikle büyüme geriliği, kardiyak anomaliler, tipik yüz görünümü ve nörokognitif sorunlarla karakterizedir. Tanı, klinik değerlendirme ve genetik testlerin birleşimiyle konulurken, tedavi yaklaşımları şu an için semptomatik destek ve onkolojik takibe odaklanmakta, genetik hedeflere yönelik çalışmalar ise sürmektedir.
Rasopathies are a group of disorders caused by genetic mutations in the RAS/MAPK signaling pathway, sharing similar clinical features. These conditions, which include Noonan, Costello, Cardiofaciocutaneous syndrome, and Neurofibromatosis type 1, are typically characterized by growth retardation, cardiac anomalies, specific facial features, and neurocognitive impairment. Diagnosis relies on a combination of clinical evaluation and genetic testing, while current treatment approaches focus on symptomatic support and oncological surveillance, with ongoing research into targeted genetic therapies.
Referanslar
Bourne, H.R., Sanders, D.A., and McCormick, F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990; 348: 125-132.
Kim YE, Baek ST. Neurodevelopmental Aspects of RASopathies. Mol Cells. 2019 Jun 30;42(6):441-447.
Li, S., Balmain, A., and Counter, C.M.. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 2018; 18: 767-777.
Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349:117-127.
Rauen, K.A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 2013; 14, 355-369.
Jafry M, Sidbury R. RASopathies. Clin Dermatol. 2020 Jul-Aug;38(4):455-461.
Hafner C, van Oers JM, Vogt T, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006;116:2201-2207.
Huson S. Neurofibromatosis: emerging phenotypes, mechanisms and management. Clin Med 2009;8(6):611-7.
van der Burgt I. Noonan syndrome. Orphanet J Rare Dis 2007;2:4.
Noonan JA. Hypertelorism with Turner phenotype: a new syndrome with associated congenital heart disease. Am J Dis Child 1968;116 (4):373-80.
Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV, et al. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement - the CFC syndrome. Am J Med Genet 1986;25(3):413-27.
Costello JM. A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 1977;13(2):114-8.
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29(4):465-8.
Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis and management guidelines. Pediatr 2010;126(4): 746-59.
Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010;1:2-26.
Witt DR, McGillivray BC, Allanson JE, et al. Bleeding diathesis in Noonan syndrome: a common association. Am J Med Genet 1988;31: 305-317.
Wyre HW. Cutaneous manifestations of Noonan’s syndrome. Arch Dermatol 1978;114:929-930.
Joyce S, Gordon K, Brice G, et al. The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Eur J Hum Genet 2016;24:690- 696.
Yapijakis C, Pachis N, Natsis S, et al. Is neurofibromatosis type 1- Noonan syndrome a phenotypic result of combined genetic and epigenetic factors? In Vivo 2016;30:315-320.
Reig I, Boixeda P, Fleta B, et al. Neurofibromatosis-Noonan syndrome: case report and clinicopathogenic review of the Neurofibromatosis-Noonan syndrome and RAS-MAPK pathway. Dermatol Online J 2011;17:4.
Yapijakis C, Pachis N, Voumvourakis C. Neurofibromatosis-Noonan syndrome: a possible paradigm of the combination of genetic and epigenetic factors. Adv Exp Med Biol 2017;987:151-159.
De Luca A, Bottillo I, Sarkozy A, et al. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 2005;77:1092-1.
Digilio MC, Sarkozy A, de Zorzi A, et al. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A 2006;140:740- 746.
Legius E, Schrander-Stumpel C, Schollen E, et al. PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002;39:571-574.
Sarkozy A, Conti E, Digilio MC, et al. Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet 2004;41, e68.
Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008;3:13.
Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med 2012;14:285-292.
Mancini GM, van Diggelen OP, Kleijer WJ, et al. Studies on the pathogenesis of Costello syndrome. J Med Genet 2003;40, e37.
Hennekam RC. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 2003;117C:42-48.
Costello Syndrome - NORD (National Organization for Rare Disorders). 2018. https://rarediseases.org/rare-diseases/costello-syndrome.
Kim YE, Baek ST. Neurodevelopmental Aspects of RASopathies. Mol Cells. 2019 Jun 30;42(6):441-447.
Roberts A, Allanson J, Jadico SK, et al. The cardiofaciocutaneous syndrome. J Med Genet 2006;43:833-842.
Pierpont ME, Magoulas PL, Adi S, et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2014;134:e1149-e1162.
van Den Berg H, Hennekam RC. Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. J Med Genet 1999;36:799-800.
Kratz CP, Rapisuwon S, Reed H, et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011;157C:83-89.
Rauen KA. Cardiofaciocutaneous Syndrome. University of Washington, Seattle: GeneReviews. 2012.
Koh, H.Y., Kim, S.H., Jang, J.,et al. BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors. Nat. Med. 2018;24, 1662- 1668.
Yoon, G., Rosenberg, J., Blaser, S., and Rauen, K.A. Neurological complications of Cardio-Facio-Cutaneous syndrome. Dev. Med. Child Neurol.2007; 49, 894-899.
Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61:1-14. quiz 15-16.
Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 1996;33:2-17.
Hüffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A. A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A. 2006; 140A:2749–56.
Stevenson DA, Viskochil DH, Rope AF, Carey JC. Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet. 2006; 69:246–53.
Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol 2015;132:75-86.
Adil A, Singh AK. Neurofibromatosis Type 1. 2021 May 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61:1-14. quiz 15-16.
Stevenson D, Viskochil D, Mao R. Legius syndrome. University of Washington, Seattle: GeneReviews. 2015.
Brems H, Pasmant E, Van Minkelen R, et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 2012;33: 1538-1546.
Muram-Zborovski TM, Stevenson DA, Viskochil DH, et al. SPRED 1 mutations in a neurofibromatosis clinic. J Child Neurol 2010 Oct;25(10):1203-9.
Denayer E, Chmara M, Brems H, et al. Legius syndrome in fourteen families. Hum Mutat 2011;32:1985-98.
Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol 2014;134:2493-2496.
Prieto-Barrios M, Llamas-Martin R, Velasco-Tamariz V, et al. Phacomatosis pigmentokeratotica: a case of HRAS mosaicism causing rhabdomyosarcoma. Br J Dermatol 2018;17.
Eerola I, Boon LM, Mulliken JB, et al. Capillary malformationarteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003;73:1240- 1249.
Revencu N, Boon LM, Mendola A, et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformationarteriovenous malformation. Hum Mutat 2013;34:1632-1641.
Digilio MC, Lepri F, Baban A, et al. RASopathies: clinical diagnosis in the first year of life. Mol Syndromol 2011;1:282-289.
Leung GKC, Luk HM, Tang VHM, et al. Integrating functional analysis in the next-generation sequencing diagnostic pipeline of RASopathies. Sci Rep 2018;8:2421.
Bhoj EJ, Yu Z, Guan Q, et al. Phenotypic predictors and final diagnoses in patients referred for RASopathy testing by targeted next-generation sequencing. Genet Med 2017;19:715-718.
Ütine GE, RASopatiler: Nöro-Kardiyo-Fasiyo-Kutanöz Sendromlar, Türkiye Klinikleri J Pediatr Sci 2011;7(2):92-8.
Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008;300:287-294.
Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011;45:241-245.
Rauen KA, Banerjee A, Bishop WR, et al. Costello and cardio-faciocutaneous syndromes: moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 2011;157C:136-146.
